Pedia Loss
This article was originally published in The Tan Sheet
Executive Summary
Feb. 4 congressional letter to pediatric appetite suppressant marketer Dynamic Health Products marks expansion of House Energy & Commerce/Oversight & Investigations Subcommittee inquiry into dietary supplements aimed at children. Letter from Chairman James Greenwood (R-Penn.) follows previous correspondence. Greenwood notes the company previously said Pedia Loss is no longer publicly available, yet the product is still offered on the firm's 1website. Greenwood requests DHP provide records on development, marketing and any adverse events. The subcommittee previously targeted Skinny Pill for Kids. A separate investigation by the subcommittee into ephedra culminated in high-profile hearings which reignited the debate on the adequacy of protections under DSHEA (2"The Tan Sheet" July 28, 2003, p. 5)...
You may also be interested in...
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.